Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 10398668
Glutamate treatment of cardiovascular disorders
granted -
US 10400010
Structure-based peptide inhibitors of P53 aggregation as a new approach to cancer therapeutics
granted -
US 10400045
Internalizing human monoclonal antibodies targeting prostate and other cancer cells
granted -
US 10398661
Methods for classifying a cancer as susceptible to TMEPAI-directed therapies and treating such cancers
granted -
US 10400253
Methods and compositions or RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 10391183
Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
granted -
US 10392376
Heterocyclic inhibitors of ATR kinase
granted -
US 10391126
CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
granted -
US 10392412
Platinum anticancer agents
granted -
US 10391098
Antisense antibacterial compounds and methods
granted -
US 10391142
Biomarkers for painful intervertebral discs and methods of use thereof
granted -
US 10392618
Micro-RNA family that modulates extracellular matrix genes and uses thereof
granted -
US 10391143
Mitochondrial-derived peptide MOTS3 regulates metabolism and cell survival
granted -
US 10391093
Therapeutic compounds
granted -
US 10391175
BET bromodomain inhibitors and therapeutic methods using the same
granted -
US 10392642
High molecular weight heparosan polymers and methods of production and use thereof
granted -
US 10385360
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 10385080
STAT6 inhibitors
granted -
US 10385031
Substituted piperazines as selective HDAC1,2 inhibitors
granted -
US 10383835
Treatment of inflammatory disorders in non-human mammals
granted -
US 10383830
Modulating antibacterial immunity via bacterial membrane-coated nanoparticles
granted -
US 10385395
Diagnostic tools for response to 6-thiopurine therapy
granted -
US 10383939
Light-activated compositions and methods using the same
granted -
US 10383943
Compositions and related methods for the treatment of cancer
granted -
US 10383935
Methods of making and using live attenuated viruses
granted -
US 10383940
Copper-cysteamine and methods of use
granted -
US 10376574
Compositions and methods for vaccination against influenza A virus
granted -
US 10379109
Systems and methods for high-resolution imaging
granted -
US 10376567
Fusion molecule based on TAA variant
granted -
US 10377782
Nucleotide analogs
granted -
US 10377796
Inhibition of pulmonary fibrosis with nutlin-3a and peptides
granted -
US 10376489
Wound healing
granted -
US 10378058
Diagnostic and therapeutic methods and compositions involving PTEN and breast cancer
granted -
US 10376486
Compositions and methods for reactivating latent viral infections
granted -
US 10370679
Modified immunization vectors
granted -
US 10370360
Small-molecule inhibitors targeting discoidin domain receptor 1 and uses thereof
granted -
US 10369158
Pharmaceutical packaging for estriol therapy
granted -
US 10369141
Methods of improving cell-based therapy
granted -
US 10370419
Tuberculosis vaccine compositions and related methods
granted -
US 10369192
Methods and compositions for delivery of exogenous factors to nervous system sites
granted -
US 10369229
Methods and compositions for liposomal formulation of antigens and uses thereof
granted -
US 10369103
Neuroprotective liposome compositions and methods for treatment of stroke
granted -
US 10369195
Methods and compositions for preventing and treating damage to the heart
granted -
US 10369106
Efficient aqueous encapsulation and controlled release of bioactive agents
granted -
US 10370345
Amyloid targeting agents and methods of using the same
granted -
US 10370488
Stimulus-responsive poly(lactic-co-glycolic)-based polymers and nanoparticles formed therefrom
granted -
US 10363274
Renal cell populations and uses thereof
granted -
US 10364473
Fast diagnosis and personalized treatments for acne
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory